# Tumor-educated platelets in myositis patients: screening for malignancies

Published: 18-10-2021
Last updated: 05-04-2024

We aim to investigate in a pilot study the blood platelet mRNA profiles in patients with IIM and a known malignancy.

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Pending |
| **Health condition type** | Miscellaneous and site unspecified neoplasms malignant and unspecified |
| **Study type** | Observational invasive |

## Summary

### ID

NL-OMON50252

**Source**
ToetsingOnline

**Brief title**
TEPs in myositis patients: malignancy screening

### Condition

- Miscellaneous and site unspecified neoplasms malignant and unspecified
- Neuromuscular disorders

**Synonym**
cancer, Myositis

**Research involving**
Human

### Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum
**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Malignancies, Myositis, TEPs, Tumor educated platelets

## Outcome measures

### Primary outcome

blood platelet mRNA profile

### Secondary outcome

na

# Study description

### Background summary

The screening for malignancies in patients with myositis may be improved and less invasive by novel techniques.

### Study objective

We aim to investigate in a pilot study the blood platelet mRNA profiles in patients with IIM and a known malignancy.

### Study design

Pilot study - cross sectional cohort study in ten patients

### Study burden and risks

The overall risk of this study is considered low and relate to two extra tubes during a single episode of blood sampling which is part of clinical care. Potential benefits include an improvement of cancer screening methods for patients with myositis.

# Contacts

**Public**
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL
**Scientific**
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Adults (18-64 years)
Elderly (65 years and older)

## Inclusion criteria

1. Patients with dermatomyositis (DM) and immune mediated necrotizing myopathy (IMNM) with or without a myositis specific antibody, with a known malignancy (out of a list of 16 malignancies).
2. Informed consent.

## Exclusion criteria

No informed consent
Women who are pregnant or breastfeeding

# Study design

## Design

**Study type:** Observational invasive

| | |
|---|---|
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |
| Primary purpose: | Diagnostic |

## Recruitment

NL

| | |
|---|---|
| Recruitment status: | Pending |
| Start date (anticipated): | 26-09-2021 |
| Enrollment: | 10 |
| Type: | Anticipated |

# Ethics review

Approved WMO

| | |
|---|---|
| Date: | 18-10-2021 |
| Application type: | First submission |
| Review commission: | METC Amsterdam UMC |

# Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

| Register | ID |
|---|---|
| CCMO | NL78849.018.21 |